Neoadjuvant Nivolumab +/- Ipilimumab in Patients with Oral Cavity Cancer

Preclinical/clinical data support neoadjuvant immunotherapy and PD-1/CTLA-4 inhibitor combinations. We hypothesized that a short 3-week neoadjuvant course of nivolumab (N) +/- the CTLA-4 inhibitor ipilimumab (NI) would lead to tumor response and not delay definitive surgery in patients (pts) with resectable oral cavity (OC).

Source: International Journal of Radiation Oncology * Biology * Physics - March 12, 2020 Category: Radiology Authors: J.D. Schoenfeld, G.J. Hanna, V. Jo, S. Criscitiello, B. Rawal, P.S. Catalano, N. Chau, J. Lorch, J. Kass, D. Annino, L. Goguen, B. Ross, D.N. Margalit, R.B. Tishler, R. Uppaluri, R.I. Haddad Tags: K. Kian Ang, MD, PhD, FASTRO, Commemorative Plenary Session Source Type: research